Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 7:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Sudden Sensorineural Hearing Loss Clear all
Completed Phase 1 Interventional

FX-322 in Adults With Severe Sensorineural Hearing Loss

NCT04629664
View directory record Official record
Conditions
Hearing Loss, Sensorineural, Noise Induced Hearing Loss, Sudden Hearing Loss
Interventions
FX-322, Placebo
Drug · Other
Lead sponsor
Frequency Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Novi, Michigan • Omaha, Nebraska • Amherst, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Jul 22, 2026, 7:02 AM EDT
Withdrawn Phase 2 Interventional

High Dose Oral Steroids in Sudden Sensorineural Hearing Loss

NCT03255473
View directory record Official record
Conditions
Sudden Sensorineural Hearing Loss (SSNHL)
Interventions
Dexamethasone, Prednisone
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Jul 22, 2026, 7:02 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment

NCT02809118
View directory record Official record
Conditions
Hearing Loss, Idiopathic Sudden Sensorineural
Interventions
AM-111 0.4 mg/ml, AM-111 0.8 mg/ml, Placebo
Drug · Other
Lead sponsor
Auris Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
38
States / cities
Birmingham, Alabama • Escondido, California • Fresno, California + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Jul 22, 2026, 7:02 AM EDT
Terminated Early Phase 1 Interventional

Fludrocortisone for Sudden Hearing Loss

NCT01186185
View directory record Official record
Conditions
Hearing Loss, Sensorineural
Interventions
Fludrocortisone
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 89 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 17, 2019 · Synced Jul 22, 2026, 7:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease

NCT01267994
View directory record Official record
Conditions
Sensorineural Hearing Loss, Autoimmune Inner Ear Disease
Interventions
Anakinra
Drug
Lead sponsor
Andrea Vambutas
Other
Eligibility
13 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Jul 22, 2026, 7:02 AM EDT
Not listed Early Phase 1 Interventional

Comparing Topical Tetracaine Drops to Topical Focal Phenol for Local Anesthesia During Intratympanic Steroid Injection

NCT04794842
View directory record Official record
Conditions
Intratympanic Steroid Injection, Idiopathic Sudden Sensorineural Hearing Loss, Meniere Disease
Interventions
Tetracaine 5% drops, Phenol 90% concentration
Drug
Lead sponsor
Our Lady of the Lake Hospital
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Jul 22, 2026, 7:02 AM EDT
Completed Phase 2 Interventional

The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease

NCT01950312
View directory record Official record
Conditions
Autoimmune Inner Ear Disease
Interventions
gevokizumab
Drug
Lead sponsor
XOMA (US) LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Jul 22, 2026, 7:02 AM EDT
Completed Phase 3 Interventional Results available

Sudden Deafness Treatment Trial

NCT00097448
View directory record Official record
Conditions
Sudden Deafness
Interventions
prednisone, methylprednisolone sodium succinate
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
14
States / cities
Los Angeles, California • San Diego, California • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Jul 22, 2026, 7:02 AM EDT
Recruiting Phase 4 Interventional

Oral Statins and Protection From Hearing Loss

NCT04826237
View directory record Official record
Conditions
Sudden Sensorineural Hearing Loss
Interventions
Statin, methylprednisolone, dexamethasone, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Jul 22, 2026, 7:02 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of the Effects of Anakinra in Corticosteroid-resistant Subjects With Sudden Sensorineural Hearing Loss

NCT02414152
View directory record Official record
Conditions
Hearing Loss, Sudden
Interventions
anakinra
Drug
Lead sponsor
Andrea Vambutas
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced Jul 22, 2026, 7:02 AM EDT
Completed Phase 1 Interventional

FX-322 in Adults With Age-Related Sensorineural Hearing Loss

NCT04601909
View directory record Official record
Conditions
Presbycusis, Hearing Loss, Sensorineural, Noise Induced Hearing Loss, Sudden Hearing Loss
Interventions
FX-322, placebo
Drug · Other
Lead sponsor
Frequency Therapeutics
Industry
Eligibility
66 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Sarasota, Florida • Omaha, Nebraska • Amherst, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Jul 22, 2026, 7:02 AM EDT
Completed Phase 2 Interventional Results available

FX-322 in Adults With Stable Sensorineural Hearing Loss

NCT04120116
View directory record Official record
Conditions
Sensorineural Hearing Loss, Noise Induced Hearing Loss, Sudden Sensorineural Hearing Loss
Interventions
FX-322 (One Dose), FX-322 (Two Doses), FX-322 (Four Doses), Placebo
Drug
Lead sponsor
Frequency Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
16
States / cities
Fresno, California • Torrance, California • Colorado Springs, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Jul 22, 2026, 7:02 AM EDT
Completed Phase 2 Interventional Results available

FX-322 in Adults With Acquired Sensorineural Hearing Loss

NCT05086276
View directory record Official record
Conditions
Hearing Loss, Sensorineural, Noise Induced Hearing Loss, Sudden Hearing Loss
Interventions
FX-322, Placebo
Drug
Lead sponsor
Frequency Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
26
States / cities
Tucson, Arizona • Fresno, California • Torrance, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Jul 22, 2026, 7:02 AM EDT
Completed No phase listed Observational

Single-sided Deafness and Cochlear Implantation

NCT05052944
View directory record Official record
Conditions
Hearing Loss, Hearing Loss, Sensorineural, Hearing Loss, Unilateral, Hearing Loss, Sudden, Hearing Loss, Cochlear, Hearing Loss in Left Ear, Hearing Loss in Right Ear, Labyrinthitis
Interventions
Cochlear implantation
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Baltimore, Maryland • Bethesda, Maryland • Lutherville-Timonium, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Jul 22, 2026, 7:02 AM EDT
Enrolling by invitation Early Phase 1 Interventional

Regenerative Medicine and Stem Cell-Based Interventions for Inner Ear Trauma, Tinnitus, and Sensorineural Hearing Loss

NCT07472023
View directory record Official record
Conditions
Sensorineural Hearing Loss, Tinnitus, Acoustic Trauma, Inner Ear Injury, Noise-Induced Hearing Loss, Sudden Hearing Loss, Vestibular Dysfunction
Interventions
Audiologic Monitoring, Investigational Regenerative Pharmacologic Therapy, Stem Cell Regenerative Therapy, Combination Regenerative Therapy
Other · Drug · Biological + 1 more
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2099
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Jul 22, 2026, 7:02 AM EDT